Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Medulloblastoma, Childhood, Rhabdomyosarcoma
Interventions: LY2940680; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Months to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: San Diego, California • Aurora, Colorado • Cincinnati, Ohio + 1 more

Conditions: Hepatic Impairment
Interventions: Balcinrenone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Hialeah, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Acute Ischemic Stroke (AIS)
Interventions: Placebo, scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg), scp776 (all dose levels); Drug
Lead sponsor: Silver Creek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 22
States / cities: Scottsdale, Arizona • Tucson, Arizona • Hartford, Connecticut + 18 more

Conditions: Invasive Fungal Infections
Interventions: APX001, APX001A; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Selected Advanced Solid Tumors
Interventions: EOS006215, Anticancer agent; Drug
Lead sponsor: iTeos Belgium SA; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Denver, Colorado • Sarasota, Florida

Conditions: Asthma
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Stockton, California • Boynton Beach, Florida • Miami Lakes, Florida + 5 more

Conditions: Fine Lines and Wrinkles, Skin Health, Skin Tone
Interventions: Light emitting diode treatment; Device
Lead sponsor: Therabody, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Purchase, New York

Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
Interventions: ARD103, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: ARCE Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina • Houston, Texas

Conditions: Phobias Snakes, Phobias Spiders
Interventions: Augmented reality exposure therapy; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Smoking
Interventions: Smokers cease smoking; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Hanover, New Hampshire • Burlington, Vermont

Conditions: Anhedonia
Interventions: Functional Magnetic Resonance Imaging, Effort-Expenditure for Rewards Task; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Alcohol Use Disorder
Interventions: Suvorexant, Placebo; Drug · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Universal Behavioral Supports, Teacher Training
Interventions: Multi-Tiered Systems of Support for Teacher Training; Behavioral
Lead sponsor: Western Kentucky University; Other
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bowling Green, Kentucky

Conditions: Healthy
Interventions: Remternetug (Test), Remternetug (Reference); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 3
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas

Conditions: Psychosis, Suicide, Health Care Utilization, Family Members
Interventions: Youth-Nominated Support Teams for CHR; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 12 Years to 25 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Irvine, California

Conditions: Acute HIV Infection, HIV Infections
Interventions: efavirenz, emtricitabine, and tenofovir; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Ovarian Cancer
Interventions: DMOT4039A; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 1 more

Conditions: Alcohol Consumption, Alcohol Use Disorder (AUD), Substance Use (Drugs, Alcohol), Substance Use Disorder (SUD), Condomless Sex, Unprotected Sex, High-risk Sex
Interventions: AWARE; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years to 25 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • Venice, California • Pittsburgh, Pennsylvania

Conditions: Adaptive Expertise, Error Management Training, Learning
Interventions: Error Management Training (Difficult), Error Management Training (Easy), Error Avoidance Training; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lung Cancer
Interventions: Aerobic Training, Progressive Stretching, Resistance Training, Aerobic and Resistance Training; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Palmoplantar Psoriasis, Genital Psoriasis
Interventions: Deucravacitinib, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 20
States / cities: Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 15 more

Conditions: Bladder Cancer
Interventions: Targeted Interventions for Impairments Identified During Geriatric Assessment; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Developmental Disability, Intellectual Disability
Interventions: 12-week FMS Intervention, Physical Activities & Activity Booklets (via FitFamilies app); Other · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 4 Years to 11 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Depressive Disorder, Major
Interventions: Cognitive behavioral therapy (CBT) and medication, Psychoeducation and medication; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

A Bioequivalence Study of APX001 High-load and Low-load Tablets

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors

Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

Efficacy of an LED Mask

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Bringing Exposure Therapy to Real-Life Context With Augmented Reality

Effects of Quitting Study A Test of Pre-clinical Findings

Dissociating Components of Anhedonia: A Pilot fMRI Study

Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder

Multi-Tiered Systems of Support for Teacher Training in Classroom Management

A Study of Remternetug (LY3372993) in Healthy Participants

Youth Nominated Support Team

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Implementing an Evidence-based Alcohol Use and Sexual Risk Intervention in Young Adult Homeless Service Settings

Facilitating Adaptive Expertise in Learning Computed Tomography

Lung Cancer Exercise Training Study

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer

Fit Families Multisite

Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression